OC
ALBO

Oppenheimer & Co’s Albireo Pharma Inc ALBO Stock Holding History

Oppenheimer & Co’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-667
Closed -$46K – 1493
2013
Q4 		$46K Hold
667
– – ﹤0.01% 1350
2013
Q3 		$63K Buy
+667
New +$86.8K ﹤0.01% 1273

Other funds holding ALBO

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FNYS
First New York Securities New York $53.7M AUM 57.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co's ALBO Position: Q1 2014 in Review

Oppenheimer & Co sold out of Albireo Pharma Inc (ALBO) in Q1 2014, closing a stake of 667 shares — an estimated $46K sold.

Oppenheimer & Co first reported a position in ALBO in Q3 2013 and held it in 2 quarters. The position peaked at $63K in Q3 2013. 43 funds tracked by Wall St. Rank hold ALBO as of Q1 2014.

  • Oppenheimer & Co reported no remaining Albireo Pharma Inc position as of Q1 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 667 Albireo Pharma Inc shares in Q1 2014, an estimated $46K.
  • Oppenheimer & Co first reported a position in Albireo Pharma Inc in Q3 2013 and held it in 2 quarters.
  • Oppenheimer & Co's Albireo Pharma Inc position peaked at $63K in Q3 2013.
  • 43 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2014.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.